000070926 001__ 70926
000070926 005__ 20180618105848.0
000070926 0247_ $$2doi$$a10.1186/s13567-018-0539-5
000070926 0248_ $$2sideral$$a106463
000070926 037__ $$aART-2018-106463
000070926 041__ $$aeng
000070926 100__ $$aSánchez-Sánchez, R.
000070926 245__ $$aInfluence of dose and route of administration on the outcome of infection with the virulent Neospora caninum isolate Nc-Spain7 in pregnant sheep at mid-gestation
000070926 260__ $$c2018
000070926 5060_ $$aAccess copy available to the general public$$fUnrestricted
000070926 5203_ $$aExperimental infections in pregnant sheep have been focused on studying the effect of the time of challenge on the outcome of N. caninum infection, whereas the impact of the dose and route of challenge has not been studied in depth. Therefore, clinical outcome, immune responses, parasite detection and burden, and lesion severity in placental tissues and foetal brains were investigated in 90-day-pregnant sheep inoculated intravenously with 105 (G1), 104 (G2), 103 (G3), or 102 (G4) tachyzoites or subcutaneously with 104 (G5) tachyzoites of the virulent Nc-Spain7 isolate and an uninfected group (G6). Comparing challenge doses, G1 was the only group that had 100% abortion. Likewise, IFN¿ levels in G1 increased earlier than those in other intravenously infected groups, and IgG levels on day 21 post-infection (pi) were higher in G1 than those in other intravenously infected groups. Concerning vertical transmission, G1 shows a higher parasite burden in the foetal brain than did G2 and G3. Comparing routes of administration, no differences in foetal survival rate or parasite load in the foetal brain were found. Although G2 had higher IFN¿ levels than G5 on day 10 pi, no differences were found in humoral immune responses. Because the outcome after intravenous infection with 105 tachyzoites was similar to that observed after intravenous infection with 106 tachyzoites used in a previous work (100% abortion and vertical transmission), we conclude that it may be reasonable to use 105 tachyzoites administered by the intravenous route in further experiments when assessing drugs or vaccine candidates.
000070926 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/AGL2016-75935-C2
000070926 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000070926 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000070926 700__ $$aFerre, I.
000070926 700__ $$aRe, M.
000070926 700__ $$aRegidor-Cerrillo, J.
000070926 700__ $$aBlanco-Murcia, J.
000070926 700__ $$0(orcid)0000-0003-0042-8800$$aFerrer, L.M.$$uUniversidad de Zaragoza
000070926 700__ $$aNavarro, T.
000070926 700__ $$aPizarro Díaz, M.
000070926 700__ $$aGonzález-Huecas, M.
000070926 700__ $$aTabanera, E.
000070926 700__ $$aBenavides, J.
000070926 700__ $$aOrtega-Mora, L.M.
000070926 7102_ $$11009$$2617$$aUniversidad de Zaragoza$$bDepartamento de Patología Animal$$cMedicina y Cirugía Animal
000070926 773__ $$g49 (2018), 42 [15 pp]$$pVet. res.$$tVeterinary Research$$x0928-4249
000070926 8564_ $$s1496239$$uhttp://zaguan.unizar.es/record/70926/files/texto_completo.pdf$$yVersión publicada
000070926 8564_ $$s102796$$uhttp://zaguan.unizar.es/record/70926/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000070926 909CO $$ooai:zaguan.unizar.es:70926$$particulos$$pdriver
000070926 951__ $$a2018-06-18-08:57:40
000070926 980__ $$aARTICLE